<DOC>
	<DOCNO>NCT00802854</DOCNO>
	<brief_summary>The objective study collect safety efficacy data Eraxis IV ( anidulafungin ) 100 mg accord Korea Ministry Food Drug Safety regulation .</brief_summary>
	<brief_title>Post Marketing Surveillance Study To Observe Safety And Efficacy Of EraxisÂ® IV</brief_title>
	<detailed_description>The objective study determine problem question associate Eraxis marketing , regard follow clause condition general clinical practice , compliance regulation `` Re-examination guideline new drug '' . 1 . Serious adverse event/adverse drug reaction 2 . Unexpected adverse event/adverse drug reaction reflect approved drug label . 3 . Known adverse drug reaction 4 . Non-serious adverse drug reaction 5 . Other safety effectiveness information Eraxis first approve new medicine 30 May 2008 . As required new medication approve Ministry Food Drug Safety ( MFDS ) , safety effectiveness information new medication provide certain number subject administer set routine practice initial 6 year approval ( 29 May 2014 ) . However , require subject enrol original reexamination period ( 30 May 2008 ~ 29 May 2014 ) . Therefore , accord order MFDS 02 Mar 2015 , Eraxis PMS require collect rest require subject 02 September 2016 prospective restrospective approach .</detailed_description>
	<mesh_term>Peritonitis</mesh_term>
	<mesh_term>Candidemia</mesh_term>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Abdominal Abscess</mesh_term>
	<criteria>1 . Prospective Study Population 1.1 . Inclusion Criteria Subjects must meet follow inclusion criterion eligible enrollment study : Use treatment invasive candidiasis adult patient Evidence personally sign date data privacy statement indicate subject ( legally acceptable representative ) inform pertinent aspect study . 1.2 . Exclusion Criteria Subjects present follow include study : Subjects Eraxis IV prescribe disease invasive candidiasis adult patient . Subjects le 18 age exclude study since safety effectiveness pediatric patient establish yet . Hypersensitivity active substance , excipients . Hypersensitivity medicinal product echinocandin class ( e.g . caspofungin ) . 2 . Retrospective Study Population 2.1 . Inclusion Criteria Subjects must meet one follow inclusion criterion eligible enrollment study : Since subject enrol meet usual prescribe criterion per local product document Eraxis IV time start Eraxis IV administration , inclusion criterion divide following basis 10 Mar 2015 approve indication update . In case start date Eraxis IV administration prior 10 Mar 2015 Use treatment follow fungal infection : candidemia form Candida infection ( intraabdominal abscess , peritonitis ) In case start date Eraxis IV administration 10 Mar 2015 Use treatment invasive candidiasis adult patient 2.2 . Exclusion Criteria Subjects present follow include study : Subjects Eraxis IV prescribe disease candidemia form Candida infection ( intraabdominal abscess , peritonitis ) ( case start date Eraxis IV administration prior 10 Mar 2015 ) invasive candidiasis adult patient ( case start date Eraxis IV administration 10 Mar 2015 ) . Subjects less 18 age exclude study since safety effectiveness pediatric patient establish yet . Hypersensitivity active substance , excipients . Hypersensitivity medicinal product echinocandin class ( e.g . caspofungin ) . Subjects enrol prospective phase study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>anidulafungin</keyword>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
</DOC>